Mustang Bio

Developer of CAR-T cell therapy for brain cancer and acute myeloid leukemia treatment

placeNew York City, New York, United States calendar_todayFounded 2015 groups80 employees language mustangbio.com

Registered entities

Social engagement

Social engagement: 9.4K social following, 1 post in the last 12 months — below the industry typical range.

Investor mix

4 investors on record.

Investor typeCountShare
Private equity125%
Bank & private debt125%
Other / undisclosed250%
Coming soon